Bacteria: Driving polar growth
Profiling the phenotype of 200,000 mutants revealed a new cofactor that may help a group of rod-shaped bacteria elongate and grow.
- Global Health Institute, Ecole Polytechnique Fédérale de Lausanne, Switzerland
Bacteria come in a variety of shapes and sizes – some are round, some are spiral and some are rod-shaped. The mechanisms that bacteria use to generate and maintain these diverse shapes as they grow is an area of active research (Kysela et al., 2016). The cell wall of bacteria contains a net-like structure called peptidoglycan, and it is thought that this structure maintains the shape of the cell (Egan et al., 2017). As bacteria grow, nascent peptidoglycans and other materials are inserted into the cell wall in a complicated process involving multiprotein complexes that contain various enzymes (Höltje, 1998; Pazos et al., 2017).
The process of cell wall growth has been widely studied in rod-shaped bacteria such as Escherichia coli and Bacillus subtilis, which grow by adding new material to the long sidewalls of the cell rather than to the ends (Daniel and Errington, 2003). But not all rod-shaped bacteria grow this way. For example, bacteria belonging to the Actinobacteria phylum – which includes the pathogens that cause tuberculosis, leprosy, and diphtheria – grow by adding new material to the ends (or poles) of the cell (Kieser and Rubin, 2014; Cameron et al., 2015).
It has been suggested that scaffold proteins and intermediate filaments target the machinery that synthesizes peptidoglycans to the cell poles, in order to restrict growth to this region (Letek et al., 2008; Fiuza et al., 2010). However, many aspects of polar growth, including the composition of the enzyme complexes and the cofactors involved, are still unknown. Now, in eLife, Joel Sher, Hoong Chuin Lim and Thomas Bernhardt from Harvard Medical School report how a newly discovered cofactor localizes a peptidoglycan synthase enzyme to the poles of bacterial cells (Sher et al., 2020).
To identify the components involved in polar growth, Sher et al. studied a library of 200,000 mutants of Corynebacterium glutamicum (a member of the Actinobacteria phylum) in which each strain is mutated for a specific gene or pathway. The bacteria were exposed to various stressful conditions or antibiotics, and a phenotypic profile was generated for each mutant based on how they responded. Further analysis revealed that genes which have a similar role, or work together in the same pathway, exhibit similar characteristics when mutated. This allowed Sher et al. to identify which genes are involved in polar growth.
Sher et al. studied the behavior of a previously unknown gene that codes for a protein named CofA. The phenotypic profile of CofA mutants was highly correlated with the profiles of strains carrying a genetic mutation in an enzyme called PBP1a, which synthesizes peptidoglycans. Fluorescent tagging revealed that CofA was localized at the cell poles of Corynebacterium, which is consistent with previous studies that found peptidoglycan synthases (such as PBP1a) to also be located at this region (Valbuena et al., 2007).
Individually deleting the genes that code for CofA and PBP1a showed that these two proteins depend on each other for their localization. Further experiments revealed that CofA acts as a cofactor and binds to the transmembrane domain of PBP1a, helping the enzyme accumulate at the tips of the cell.
Paralogs of the gene coding for CofA and its transmembrane domains are found throughout the Actinobacteria phylum. Sher et al. showed that CofA proteins in pathogenic bacteria, such as C. jeikium and M. tuberculosis, also interacted with their PBP1a counterpart in a specific manner. The CofA protein in M. tuberculosis was found to have an extended N-terminal cytoplasmic domain and deleting this region facilitated the interaction between CofA and PBP1a. However, the role of this N-terminal domain was not investigated further.
This study is the first to identify a conserved cofactor that modulates the behavior of peptidoglycan synthases in Actinobacteria. It also raises several tantalizing questions: Would removing CofA cause the growth of Corynebacterium to be less polar? Does deleting CofA and PBP1a change how peptidoglycan units are inserted into the cell wall? It would also be useful to mine the phenotypic profiles of other mutants to see if there are other unidentified cofactors of the PBP proteins.
Several disease-causing pathogens use this mode of polar growth, which is why it is important to study the components and mechanisms involved. The bacterial cell wall is repeatedly used as a target for antibiotic development. These findings could identify new drug targets, which may help combat the rising rates of antibiotic resistance, especially in the case of tuberculosis. Furthermore, the phenotype profiling approach used by Sher et al. could be used to determine the role of previously uncharacterized proteins and identify which proteins and genes participate in the same biological pathway.
References
-
The essential features and modes of bacterial polar growthTrends in Microbiology 23:347–353.https://doi.org/10.1016/j.tim.2015.01.003
-
Regulation of bacterial cell wall growthThe FEBS Journal 284:851–867.https://doi.org/10.1111/febs.13959
-
Phosphorylation of a novel cytoskeletal protein (RsmP) regulates rod-shaped morphology in Corynebacterium glutamicumJournal of Biological Chemistry 285:29387–29397.https://doi.org/10.1074/jbc.M110.154427
-
Growth of the stress-bearing and shape-maintaining murein sacculus of Escherichia coliMicrobiology and Molecular Biology Reviews 62:181–203.https://doi.org/10.1128/MMBR.62.1.181-203.1998
-
How sisters grow apart: mycobacterial growth and divisionNature Reviews Microbiology 12:550–562.https://doi.org/10.1038/nrmicro3299
-
DivIVA is required for polar growth in the MreB-lacking rod-shaped actinomycete Corynebacterium glutamicumJournal of Bacteriology 190:3283–3292.https://doi.org/10.1128/JB.01934-07
-
Robust peptidoglycan growth by dynamic and variable multi-protein complexesCurrent Opinion in Microbiology 36:55–61.https://doi.org/10.1016/j.mib.2017.01.006
Article and author information
Author details
Publication history
Copyright
© 2020, Dhar
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,103
- views
-
- 77
- downloads
-
- 0
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Bacteria: Driving polar growth
eLife 9:e57043.
https://doi.org/10.7554/eLife.57043
Further reading
-
- Genetics and Genomics
- Microbiology and Infectious Disease
The sustained success of Mycobacterium tuberculosis as a pathogen arises from its ability to persist within macrophages for extended periods and its limited responsiveness to antibiotics. Furthermore, the high incidence of resistance to the few available antituberculosis drugs is a significant concern, especially since the driving forces of the emergence of drug resistance are not clear. Drug-resistant strains of Mycobacterium tuberculosis can emerge through de novo mutations, however, mycobacterial mutation rates are low. To unravel the effects of antibiotic pressure on genome stability, we determined the genetic variability, phenotypic tolerance, DNA repair system activation, and dNTP pool upon treatment with current antibiotics using Mycobacterium smegmatis. Whole-genome sequencing revealed no significant increase in mutation rates after prolonged exposure to first-line antibiotics. However, the phenotypic fluctuation assay indicated rapid adaptation to antibiotics mediated by non-genetic factors. The upregulation of DNA repair genes, measured using qPCR, suggests that genomic integrity may be maintained through the activation of specific DNA repair pathways. Our results, indicating that antibiotic exposure does not result in de novo adaptive mutagenesis under laboratory conditions, do not lend support to the model suggesting antibiotic resistance development through drug pressure-induced microevolution.
-
- Cell Biology
- Microbiology and Infectious Disease
Zika virus (ZIKV) infection causes significant human disease that, with no approved treatment or vaccine, constitutes a major public health concern. Its life cycle entirely relies on the cytoplasmic fate of the viral RNA genome (vRNA) through a fine-tuned equilibrium between vRNA translation, replication, and packaging into new virions, all within virus-induced replication organelles (vROs). In this study, with an RNA interference (RNAi) mini-screening and subsequent functional characterization, we have identified insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) as a new host dependency factor that regulates vRNA synthesis. In infected cells, IGF2BP2 associates with viral NS5 polymerase and redistributes to the perinuclear viral replication compartment. Combined fluorescence in situ hybridization-based confocal imaging, in vitro binding assays, and immunoprecipitation coupled to RT-qPCR showed that IGF2BP2 directly interacts with ZIKV vRNA 3’ nontranslated region. Using ZIKV sub-genomic replicons and a replication-independent vRO induction system, we demonstrated that IGF2BP2 knockdown impairs de novo vRO biogenesis and, consistently, vRNA synthesis. Finally, the analysis of immunopurified IGF2BP2 complex using quantitative mass spectrometry and RT-qPCR revealed that ZIKV infection alters the protein and RNA interactomes of IGF2BP2. Altogether, our data support that ZIKV hijacks and remodels the IGF2BP2 ribonucleoprotein complex to regulate vRO biogenesis and vRNA neosynthesis.
